Keyword: Syros Pharmaceuticals
Seven of the 13 newly diagnosed AML patients with a certain biomarker had full complete responses after receiving the RARα agonist and Vidaza.
The lackluster results led Syros to switch its attention to an oral CDK7 inhibitor, SY-5609, that is due to enter the clinic early next year.
Blocking the enzyme CDK7 could be a new way to overcome resistant prostate cancer, and one drug is already in trials.
The clinical trial recorded one partial or complete response among the 48 evaluable patients, wiping 50% off Syros’ stock.
Syros Pharmaceuticals aims to use small molecules to control the activation and repression of genes. Now, it has raised $50 million in an IPO to get proof-of-concept data.